Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

Dose-Dependent Effects of Recombinant Human Interleukin-11 on Contractile Properties in Rabbit 2,4,6-Trinitrobenzene Sulfonic Acid Colitis

Inge Depoortere, Theo Thijs, Gert Van Assche, James C. Keith Jr. and Theo L. Peeters
Journal of Pharmacology and Experimental Therapeutics September 2000, 294 (3) 983-990;
Inge Depoortere
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theo Thijs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gert Van Assche
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James C. Keith Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Theo L. Peeters
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

We studied the effect of recombinant human interleukin-11 (rhIL-11), a cytokine with protective effects against injury to the intestinal mucosa, on inflammatory changes in the muscle layers of the gut, in rabbits with colitis. A single dose of rhIL-11 (4, 40, or 720 μg/kg) was given 1 h before colitis was induced with 135 mg/kg 2,4,6-trinitrobenzene sulfonic acid (TNBS), followed by a continuous s.c. administration of 4, 40, or 720 μg/kg · day rhIL-11 or saline for 5 days. Colitis affected mucosal architecture, general mechanical properties (passive tension increased with 12.3 g/mm2, optimal stretch decreased with 26%), and collagen content (decreased from 366 ± 25 to 237 ± 13 μg/mg of protein). Changes in passive tension and collagen content were normalized by the highest and lowest dose of rhIL-11, respectively, but neither dose could normalize the optimal stretch. Colitis also decreased maximal contractile tension in response to acetylcholine (ACh), motilin, substance P (SP), K+, and prostaglandin E2 but this was normalized with 40 μg/kg · day (motilin, SP) and 720 μg/kg · day (ACh, K+) rhIL-11 but not for prostaglandin E2. For motilin and SP, receptor density was decreased in colitis and normalized in treated rabbits. Colitis also increased the contractile potency toward ACh, an effect already reversed by rhIL-11, 4 μg/kg · day. In conclusion, rhIL-11 partially normalizes disturbed tension generation in experimental colitis. The use of this cytokine in the treatment of irritable bowel disease may contribute to the restoration of motor dysfunction.

Footnotes

  • Send reprint requests to: Theo L. Peeters, Centre for Gastroenterological Research, Gasthuisberg O & N, B-3000 Leuven, Belgium. E-mail: theo.peeters{at}med.kuleuven.ac.be

  • ↵1 This study was supported by grants from the Fund for Scientific Research-Flanders (Belgium) (FWO Grant G 0109.00) and the Belgian Ministry of Science (GOA 98/011 and IUAP P4/16). I.D. is a postdoctoral research fellow of the Fund for Scientific Research-Flanders. This work has been presented at the American Gastroenterological Association in New Orleans (Depoortere et al., 1998).

  • Abbreviations:
    IL
    interleukin
    TNF-α
    tumor necrosis factor-α
    TNBS
    2,4,6-trinitrobenzene sulfonic acid
    CD
    Crohn's disease
    rhIL-11
    recombinant human interleukin-11
    ACh
    acetylcholine
    SP
    substance P
    PGE2
    prostaglandin E2
    IBD
    irritable bowel disease
    IL-RA
    interleukin receptor antagonist
    COX-2
    cyclooxygenase-2
    PCR
    polymerase chain reaction
    GAPDH
    glyceraldehyde-3-phosphate dehydrogenase
    UC
    ulcerative colitis
    NK
    neurokinin
    • Received January 21, 2000.
    • Accepted May 2, 2000.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 294 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 294, Issue 3
1 Sep 2000
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Dose-Dependent Effects of Recombinant Human Interleukin-11 on Contractile Properties in Rabbit 2,4,6-Trinitrobenzene Sulfonic Acid Colitis
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

Dose-Dependent Effects of Recombinant Human Interleukin-11 on Contractile Properties in Rabbit 2,4,6-Trinitrobenzene Sulfonic Acid Colitis

Inge Depoortere, Theo Thijs, Gert Van Assche, James C. Keith and Theo L. Peeters
Journal of Pharmacology and Experimental Therapeutics September 1, 2000, 294 (3) 983-990;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY

Dose-Dependent Effects of Recombinant Human Interleukin-11 on Contractile Properties in Rabbit 2,4,6-Trinitrobenzene Sulfonic Acid Colitis

Inge Depoortere, Theo Thijs, Gert Van Assche, James C. Keith and Theo L. Peeters
Journal of Pharmacology and Experimental Therapeutics September 1, 2000, 294 (3) 983-990;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Lipopolysaccharide Induces Epithelium- and Prostaglandin E2-Dependent Relaxation of Mouse Isolated Trachea through Activation of Cyclooxygenase (COX)-1 and COX-2
  • Cannabinoid-Mediated Elevation of Intracellular Calcium: A Structure-Activity Relationship
  • Protease-Activated Receptor-2 Peptides Activate Neurokinin-1 Receptors in the Mouse Isolated Trachea
Show more INFLAMMATION AND IMMUNOPHARMACOLOGY

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics